LARGO, Fla., Jan. 31 /PRNewswire-FirstCall/ -- GeoPharma, Inc. announced today that it has in-licensed technology from The University of Florida Office of Technology Licensing for development of a novel therapeutic for Primary or Idiopathic Pulmonary Hypertension (PPH).
The compound is a synthetic peptide with efficacy established through in vitro data and studies in situ animal lung models. Further studies are in progress and a patent on the compound has been filed.
PPH is an aggressive, devastating disease with limited improvement in quality of patient's life with current therapy. A mean age of onset of PPH is 36 years and a mortality of greater than 30 percent over 4 years. PPH is a disorder predominantly affecting the small pulmonary arteries, which is characterized by vascular obstruction and variable presence of vasoconstriction (constriction or narrowing of blood vessels).
Dr. Kotha Sekharam, president of GeoPharma stated, "The in-licensing of this compound follows our strategy of developing novel therapeutics for niche markets with high barriers to entry. We have demonstrated the ability to both develop research in-house, as well as identify external research with commercial potential."
About University of Florida Office of Technology Licensing
The University of Florida's Office of Technology Licensing (OTL) is the University's main commercialization center. It receives almost 300 disclosures per year generated from the cutting-edge research that takes place from all around the campus. OTL has partnered with companies throughout Florida, the Southeast and nationally to assist in the movement of technologies to the marketplace and welcomes the opportunity to work with companies interested in such a partnership. For more information, visit the website at www.otl.uf.edu.
About GeoPharma
GeoPharma, Inc. is a rapidly growing pharmaceutical company specializing in the manufacturing and distribution of over-the-counter, nutritional, generic drug and functional food products. The company's growth strategy is to capitalize on its manufacturing expertise to develop high margin generic or novel drugs for niche markets with high barriers to entry. GeoPharma's competitive advantage lies in its ability to circumvent or overcome the challenges in these markets. For more about GeoPharma, Inc., go to our websites at www.onlineihp.com and www.carbslim.com.
This press release may contain statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.
GeoPharma, Inc.CONTACT: Carol Dore-Falcone, VP/CFOT of GeoPharma, +1-727-544-8866 ext.244, or cdf@onlineihp.com; or Investor and Media Relations: Rachel Levineof The Global Consulting Group, +1-646-284-9439, or rlevine@hfgcg.com
